“The cannabinoid 1(CB1 ) receptor inverse agonists/antagonists, rimonabant (SR141716, SR) and AM251, produce nausea and potentiate toxin-induced nausea by inverse agonism (rather than antagonism) of the CB1 receptor. Here, we evaluated two phytocannabinoids, cannabidivarin (CBDV) and Δ9 -tetrahydrocannabivarin (THCV) for their ability to produce these behavioural effects characteristic of CB1 receptor inverse agonism in rats.
…we investigated the potential of THCV and CBDV to produce conditioned gaping (measure of nausea-induced behaviour),..
THC, THCV and CBDV suppressed LiCl-induced conditioned gaping, suggesting anti-nausea potential…
The pattern of findings indicates that neither THCV nor CBDV produced a behavioural profile characteristic of CB1 receptor inverse agonists.
As well, these compounds may have therapeutic potential in reducing nausea.”